TY - JOUR
T1 - Medical attitudes survey for female dystrophinopathy carriers in Japan
AU - Kobayashi, Michio
AU - Hatakeyama, Tomoyuki
AU - Ishizaki, Masatoshi
AU - Adachi, Katsuhito
AU - Morita, Mizuki
AU - Yonemoto, Naohiro
AU - Matsumura, Tsuyoshi
AU - Toyoshima, Itaru
AU - Kimura, En
N1 - Funding Information:
This work was supported in part by an Intramural Research Grant for Neurological and Psychiatric Disorders of the NCNP (26-7).
Publisher Copyright:
© 2018 The Japanese Society of Internal Medicine.
PY - 2018
Y1 - 2018
N2 - Objective This study attempted to clarify the current status of female dystrophinopathy carriers, including the numbers of patients, the status of genetic screening, the status of counseling, physicians’ understanding, and barriers to registration. Methods We sent out questionnaires to 402 physicians registered in the Remudy dystrophinopathy registry. The total number of responses received was 130 (response rate: 32%). Result In total, 1,212 cases of Duchenne muscular dystrophy, 365 cases of Becker muscular dystrophy, and 132 cases of female dystrophinopathy with a confirmed genetic mutation were encountered, and genetic testing was performed in the mother in 137, 23, and 12 cases, respectively. With respect to the risk of the onset of health problems, 25% of physicians always explained, 29% usually explained, 29% sometimes explained, and 13% never explained the risk to the mothers and female siblings of dystrophinopathy patients. The most common reason for not explaining the risk was a lack of knowledge/information. Thirty-five percent were familiar with the guidelines for testing the heart function of carriers. Conclusion Fewer mothers of dystrophinopathy patients have undergone genetic testing in Japan than in other countries. A significant portion of doctors did not explain the risks of health problems due to a lack of knowledge. We hope this survey will lead to an increased discussion of female dystrophinopathy patients.
AB - Objective This study attempted to clarify the current status of female dystrophinopathy carriers, including the numbers of patients, the status of genetic screening, the status of counseling, physicians’ understanding, and barriers to registration. Methods We sent out questionnaires to 402 physicians registered in the Remudy dystrophinopathy registry. The total number of responses received was 130 (response rate: 32%). Result In total, 1,212 cases of Duchenne muscular dystrophy, 365 cases of Becker muscular dystrophy, and 132 cases of female dystrophinopathy with a confirmed genetic mutation were encountered, and genetic testing was performed in the mother in 137, 23, and 12 cases, respectively. With respect to the risk of the onset of health problems, 25% of physicians always explained, 29% usually explained, 29% sometimes explained, and 13% never explained the risk to the mothers and female siblings of dystrophinopathy patients. The most common reason for not explaining the risk was a lack of knowledge/information. Thirty-five percent were familiar with the guidelines for testing the heart function of carriers. Conclusion Fewer mothers of dystrophinopathy patients have undergone genetic testing in Japan than in other countries. A significant portion of doctors did not explain the risks of health problems due to a lack of knowledge. We hope this survey will lead to an increased discussion of female dystrophinopathy patients.
KW - Carrier
KW - Duchenne muscular dystrophy
KW - Genetic diagnosis
KW - Health management
KW - Patient registry
UR - http://www.scopus.com/inward/record.url?scp=85051744951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051744951&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.0163-17
DO - 10.2169/internalmedicine.0163-17
M3 - Article
C2 - 29526935
AN - SCOPUS:85051744951
SN - 0918-2918
VL - 57
SP - 2325
EP - 2332
JO - Internal Medicine
JF - Internal Medicine
IS - 16
ER -